Heska Corporation (HSKA) Scheduled to Post Quarterly Earnings on Thursday
Heska Corporation (NASDAQ:HSKA) will issue its quarterly earnings data before the market opens on Thursday, November 2nd. Analysts expect the company to announce earnings of $0.39 per share for the quarter.
Heska Corporation (NASDAQ:HSKA) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.07. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The company had revenue of $34.30 million for the quarter, compared to analysts’ expectations of $33.35 million. During the same period in the previous year, the firm posted $0.35 EPS. Heska Corporation’s revenue was up 14.3% compared to the same quarter last year. On average, analysts expect Heska Corporation to post $2.01 EPS for the current fiscal year and $2.1 EPS for the next fiscal year.
Heska Corporation (NASDAQ HSKA) traded up 0.336% during midday trading on Tuesday, reaching $96.985. The company had a trading volume of 6,115 shares. The stock has a market capitalization of $700.81 million, a PE ratio of 49.432 and a beta of 0.85. Heska Corporation has a 1-year low of $51.00 and a 1-year high of $115.00. The firm’s 50 day moving average is $93.81 and its 200 day moving average is $97.87.
In other news, EVP Nancy Wisnewski sold 825 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $102.21, for a total transaction of $84,323.25. Following the completion of the transaction, the executive vice president now directly owns 38,114 shares of the company’s stock, valued at approximately $3,895,631.94. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO John Mcmahon sold 2,608 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total transaction of $263,851.36. Following the transaction, the chief financial officer now directly owns 193 shares of the company’s stock, valued at $19,525.81. The disclosure for this sale can be found here. 14.70% of the stock is currently owned by company insiders.
A number of equities research analysts have recently issued reports on HSKA shares. BidaskClub downgraded shares of Heska Corporation from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. B. Riley reiterated a “neutral” rating and set a $85.00 price target on shares of Heska Corporation in a research report on Friday, July 28th. Aegis lifted their price target on shares of Heska Corporation from $114.50 to $129.50 and gave the company a “buy” rating in a research report on Tuesday, August 1st. Benchmark Co. lifted their price target on shares of Heska Corporation from $106.00 to $120.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, Zacks Investment Research upgraded shares of Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 price target for the company in a research report on Friday, August 4th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Heska Corporation currently has a consensus rating of “Hold” and an average target price of $106.83.
TRADEMARK VIOLATION WARNING: “Heska Corporation (HSKA) Scheduled to Post Quarterly Earnings on Thursday” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/31/heska-corporation-hska-scheduled-to-post-quarterly-earnings-on-thursday.html.
About Heska Corporation
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Stock Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related stocks with our FREE daily email newsletter.